The Faculty

review course

PETROS LEVOUNIS, MD, MA, FASAM (Chair)

Petros Levounis, MD, MA, is Chair of the Department of Psychiatry at Rutgers New Jersey Medical School and Chief of Service at University Hospital in Newark, New Jersey. Previously, Dr. Levounis was on the faculty of New York University and Columbia University, where he served as Director of the Addiction Institute of New York and Chief of Addiction Psychiatry at St. Luke's and Roosevelt Hospitals from 2002 to 2013. Dr. Levounis has published numerous articles, monographs, and book chapters; has lectured extensively on addiction topics throughout the United States and abroad; has been interviewed by all the major TV networks; and has authored and edited several books. 

Dr. Levounis is a Phi Beta Kappa graduate of Stanford University where he studied Chemistry and Biophysics as a combined BS/MS student, before receiving his medical education at Stanford University School of Medicine and the Medical College of Pennsylvania. During medical school, he researched the effects of social class on patient-physician relationships in Oxford, England, and received an MA degree in Sociology from Stanford. Dr. Levounis graduated from the Columbia University residency training program earning the National Institute of Mental Health Outstanding Resident Award and went on to complete his fellowship in Addiction Psychiatry at New York University.

ABIGAIL HERRON, DO (Vice Chair)

Dr Abigail J. Herron is the Medical Director of Trinity House, an intensive outpatient addiction treatment program, the Director of the Fellowship in Addiction Medicine, and the Acting Medical Director of the Addiction Institute of New York at Mt. Sinai St. Luke’s and Roosevelt Hospitals. She is board certified in adult psychiatry and addiction psychiatry, and is an Assistant Professor in Psychiatry at Mt. Sinai School of Medicine.

Dr. Herron graduated from Wesleyan University and the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.  She completed residency at St. Luke's and Roosevelt Hospitals, where she was also chief resident, and fellowship at Columbia University and the New York State Psychiatric Institute. Her academic interests include treatment of co-occurring disorders, women’s health, and medical education.  She is the co-editor of the recently released Addiction Casebook, and the editor of ASAM’s Principles of Addiction Medicine: The Essentials.  Dr. Herron is also in private practice in New York City. 

PAUL EARLEY, MD, FASAM (Immediate Past Chair)

Dr. Earley has been an Addiction Medicine Physician for over 28 years. He is currently the Medical Director of the Georgia Professionals Health Program, Inc. and a principal with Earley Consultancy, LLC, a training and consulting firm. He specializes in the assessment and treatment of health care professionals. As a therapist, he works with patients already in recovery, providing long term therapy for those who suffer from this disease. 

Dr. Earley is a dynamic speaker and educator; he frequently lectures on the topics of addiction, particularly among health care professionals and the treatments available.  In addition, he has travelled internationally to provide training to therapists about neurobiological substrates of psychotherapy. He is the author numerous books and articles on addiction and its treatment. Dr. Earley is a Fellow of ASAM and has been on the board of ASAM for over 10 years. He is one of the authors of the American Society of Addiction Medicine (ASAM) Textbook: Principles of Addiction Medicine, including the chapter: Physician Health Programs and Addiction among Physicians.  

TIMOTHY BRENNAN, MD, MPH

Timothy Brennan, MD, MPH is an Attending Physician and Associate Fellowship Director at The Addiction Institute of New York at Roosevelt Mount Sinai Hospital in New York City. He completed his fellowship in Addiction Medicine at The Addiction Institute, a fellowship in Medical Ethics at Harvard Medical School, and a residency in Pediatrics at New York Presbyterian Hospital / Weill Cornell. He also completed an intern year in Internal Medicine at Georgetown University Hospital. Dr. Brennan has spoken at local, state and national levels about addiction issues, particularly as related to young adults.  He is the co-editor of the forthcoming Essentials of Addiction Medicine.   He received a B.S. in Foreign Service at Georgetown University, and a combined M.D./M.P.H from Tulane University School of Medicine and School of Public Health and Tropical Medicine.

JAMES FINCH, MD, FASAM

James Finch, MD obtained his medical training at the University of South Florida College of Medicine and his residency training in Family Medicine at Lancaster General Hospital in Pennsylvania. Following a Faculty Development Fellowship at Duke University, he stayed on with the Duke Family Medicine Residency Program and with joint appointments in Family Medicine and Psychiatry, helped found and was Assistant Director of the Duke Addictions Program.  He is a Fellow of the American Society of Addiction Medicine, the Immediate Past President of the NC Society of Addiction Medicine and the Director of Physician Education for the NC Governor’s Institute on Substance Abuse.

After leaving Duke, Dr. Finch worked for many years in public sector mental health and substance abuse treatment and currently directs a private Addiction Medicine practice in Durham, NC called “Changes By Choice.”He has continued to be active in local, national and international training initiatives, including the PCSS mentoring systems for buprenorphine and other opoiods, the SAMHSA sponsored Safe Opioid Prescribing workshops, and ongoing NC SBIRT initiatives in primary care and emergency room settings. He is the Clinical Training Director for Project Lazarus Community Care NC, a statewide initiative for safer use of opioid and other controlled medications. 

ELIOT GARDNER, PhD

Dr. Gardner received his undergraduate training at Harvard University, followed by graduate studies in neuroscience and physiological psychology at McGill University and the Montreal Neurological Institute.  In 1972, He was promoted to faculty rank at Albert Einstein College of Medicine in New York City, and remained there for 30 years, rising in rank to Professor of Neuroscience, Professor of Psychiatry, Director of Basic Research in Psychiatry, and Co-Director of the Addiction Psychiatry Fellowship Program.  In 2000, Dr. Gardner joined the Intramural Research Program of the National Institute on Drug Abuse and in 2003, he was appointed Chief of the Neuropsychopharmacology section, with responsibility for developing neurobiology-based medication for the treatment of addiction.  His recent research has focused heavily on the brain =s dopamine D3 receptor system, the brain’s metabotropic glutamate signaling system, and the brain’s endocannabinoid system as possible targets for anti-addiction, anti-craving, and anti-relapse medication development.

He has served as a scientific consultant to both the American and Canadian governments, and is the author of more than 400 publications in neuropsychopharmacology and addiction medicine.  He is a recipient of the prestigious Career Scientist Award of the Health Research Council of New York, and is a Fellow of the American Psychological Association. He was named A Distinguished Basic Science Scholar of the Year by the American Academy of Addiction Psychiatry.  Dr. Gardner is a member of the American, Canadian, and International Societies of Addiction Medicine.  

DAVID MEE-LEE, MD

David Mee-Lee, MD is a board-certified psychiatrist and is certified by the American Board of Addiction Medicine (ABAM). Dr.Mee-Lee has led the development of the ASAM Criteria for the Treatment of Substance-Related Disorders since the late 1980’s. He co-authored the first and second editions and is Chief Editor of ASAM PPC-2R (2001) and the new edition of The ASAM Criteria (2013). He is also Senior Vice President of The Change Companies. 

Dr. Mee-Lee is based in Davis, CA and is involved in providing training and consulting services to both provider and practitioner groups; county, state and national agencies and organizations; as well as managed care companies.  For over 30 years, he has focused on developing and promoting innovative behavioral health treatment that values clinical integrity, high quality, and cost-consciousness. More recently he has embarked upon changing the treatment and community culture from sick-care to health and wellness; and is Vice President of the Institute for Wellness Education.  He is also a Senior Fellow, Justice Programs Office (JPO) of the School of Public Affairs (SPA) at American University, Washington, DC. Past academic appointments have included clinical affiliations in the Departments of Psychiatry at Harvard University, the University of Hawaii and the University of California, Davis.

MICHAEL MILLER, MD, FASAM

Michael M. Miller, MD, FASAM, FAPA, is the medical director of the Herrington Recovery Center at Rogers Memorial Hospital in Oconomowoc, WI. He is a board-certified general psychiatrist and addiction psychiatrist and is board certified in addiction medicine by the American Board of Addiction Medicine (ABAM). He is a Fellow of the American Psychiatric Association (APA) and the American Society of Addiction Medicine (ASAM). Dr. Miller is also an at-large director of ABAM and The ABAM Foundation. He is also a past president of ASAM and a 2013 recipient of The ASAM Award. He was named Clinician of the Year by Addiction Professional for 2011 and has been included in Best Doctors in America since 2007. Dr. Miller has served on many task forces and councils of ASAM and the Wisconsin Medical Society (WMS) and is current Vice Speaker of the WMS House of Delegates. 

Dr. Miller began his residency in 1979 at the Medical College of Wisconsin (MCW) and finished at the University of Minnesota where he completed a fellowship in Chemical Dependency. He serves as a faculty member for the Addiction Psychiatry Fellowship and the new Addiction Medicine Fellowship at the University of Wisconsin School of Medicine and Public Health, where he is an Associate Clinical Professor. He also serves on the faculty for the Addiction Psychiatry Fellowship at MCW where he is an Assistant Clinical Professor. Dr. Miller was the long-time chair of the ASAM Public Policy Committee, co-chaired ASAM's Medical Specialty Action Group (MSAG), and currently chairs its Descriptive and Diagnostic Terminology Action Group (DDTAG) and its Practice Improvement and Performance Measurement Action Group (PIPMAG). 

LEENA MITTAL, MD

Leena Mittal, MD is an instructor at Harvard Medical School and Director of the Reproductive Psychiatry Consultation Service at Brigham and Women’s Hospital where she works closely with obstetric colleagues and teaches Harvard medical students, residents and fellows about perinatal and medical psychiatry.  She is a graduate of the Harvard Longwood Psychiatry Residency Training Program and has completed a fellowship in Psychosomatic Medicine at Brigham and Women’s Hospital.  

Dr Mittal’s clinical and academic interests include development of embedded and collaborative care models to provide care for complex perinatal patients with mental health needs including a buprenorphine treatment program for opioid dependent pregnant and postpartum women embedded within a prenatal care setting as well as a perinatal mental health program within the Neonatal Intensive Care Unit.  Dr.Mittal will also serve as the director of the Boston hub of a statewide perinatal depression consultation care program called MCPAP for Moms.

AYKUT OZDEN, MD

Aykut Ozden MD was born and raised in Ankara, Turkey. After completing medical school at Hacettepe University and psychiatry residency at University of Ankara, he moved to USA in 1997 to pursue his career here. He completed psychiatry residency and addiction psychiatry fellowship at Beth Israel Medical Center and child and adolescent psychiatry fellowship at Columbia University, NY Psychiatric Institute. He became board-certified in all three areas and has also become an active member of ASAM and AACAP. 

Dr. Ozden has worked closely with adolescents who were dually-diagnosed, as well patients with cannabis and opioid use disorders. Being a child and adolescent psychiatrist and an addiction psychiatrist, his focus and main interest has been teenagers with a variety of substance use disorders, as well as prevention of developing addictions. He has published and presented since early 1990's and currently works at Mt. Sinai St. Luke's and Mt. Sinai Roosevelt hospital as the director of Comprehensive Assessment Center. He is also the associate director of child and adolescent psychiatry division in the psychiatry department at the same hospital. Dr. Ozden is an assistant professor of clinical psychiatry at Icahn School of Medicine at Mt. Sinai. 

RICARDO RESTREPO, MD, MPH

Ricardo Restrepo Guzman MD, MPH completed medical school in Medellin, Colombia, and completed his residency training In Psychiatry at Boston University Medical Center along with a fellowship in Addiction Psychiatry at the same institution. He received a Master's degree in Global Public Health from New York University in 2008, while working at St. Luke's Roosevelt Hospital Center where he was the Director of the Addiction Psychopharmacology Clinic at the Addiction Institute of New York, as well as Attending Psychiatrist at the Adult Outpatient Clinic. He remains affiliated with the Addiction Institute of New York as a faculty member. He is board certified in Psychiatry and Addiction Psychiatry.

In 2012 he started to work at the Long Beach VA Hospital, where he is the Medical Director of the Substance Abuse Treatment Program/Buprenorphine Clinic as well as an Attending Psychiatrist at the Department of Mental Health. He teaches and supervises students, psychiatry, family medicine residents and staff at the Long Beach VA Hospital and works with the diverse population of Los Angeles and Orange Counties. Dr.Restrepo is the Assistant Clinical Professor of Psychiatry and Human Behavior at the University of California Irvine, School of Medicine. His academic interests include the psychotherapy and psychopharmacology of addiction and transcultural issues related to psychiatry, human rights, and behavioral addictions. He has also served as a United Nations consultant since 2005.

EDWIN SALSITZ, MD, FASAM

Edwin A. Salsitz, MD, FASAM, has been an attending physician in the Beth Israel Medical Center, Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Medicine at the Mount Sinai School of Medicine.  He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project.  Dr.Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease.  He has published and lectures frequently on addiction medicine topics. 

Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings, and is a mentor in the PCSS-MAT mentoring program.  He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, The ASAM State of the Art course, and is a reviewer for the Journal of Addiction Medicine. Dr.Salsitz is also the recipient of the 2014 ASAM Annual Award. He is also the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee.  Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services.

JEFFERY SELZER, MD, FASAM

Jeffrey Selzer, MD, FASAM has been Medical Director of Committee for Physician Health, New York State’s physician health program, since 2008.  Dr. Selzer is also Director of Physicians’ Resource Network, a confidential counseling service for medical staff members of the North Shore- Long Island Jewish Health System.  Prior to taking on these roles, Dr. Selzer was the Director of Addiction Treatment Services for the North Shore- Long Island Jewish Health System and Medical Director of Zucker Hillside Hospital.  He attended medical school at the University of Michigan and completed a psychiatric residency at the University of California at Los Angeles.  He served on the Executive Committee for the National Institute on Drug Abuse Clinical Trials Network.   He has served as a Board Member of the Federation of State Physician Health Programs and is currently Co-Chair of the Federation’s Research Committee.   In 2013, Dr. Selzer was elected to the Board of the American Society of Addiction Medicine as Region 1 Director.

Dr. Selzer has faculty appointments as an associate professor at the Hofstra North Shore – LIJ and Albert Einstein Medical Schools where he teaches both medical students and residents. He has participated in addiction medicine research as a member of protocol development teams, site principle investigator, and as the author of research publications.  He is an Editorial Board Member of the Journal of Substance Abuse Treatment and is a reviewer for the Journal of Addiction Medicine. He is also  an editor with Nunes, Levounis, and Davies of Substance Dependence and Co-Occurring Psychiatric Disorders: Best Practices for Diagnosis and Treatment.

SHARON STANCLIFF, MD

Sharon Stancliff, MD, FAAFP is the Medical Director of the Harm Reduction Coalition, a national training and advocacy organization; she is based in New York City. Her interest in drug user health was catalyzed when she was providing primary care to drug users with AIDS in the early 1990’s. Dr. Stancliff graduated from the School of Medicine at University of California at Davis, did her Family Practice residency at the University of Arizona and completed the AIDS Institute-sponsored Nicolas Rango HIV Clinical Scholars Program at Beth Israel Medical Center in New York City.  She is board certified in Family Medicine, a Fellow of the American Academy of Family Practice, and certified by the American Board of Addiction Medicine. 

Dr. Stancliff is currently funded by the AIDS Institute, New York State Department of Health and the New York City Department of Health to provide overdose prevention services with naloxone, both directly through education and capacity building. She also provides consultation on drug treatment, harm reduction and overdose prevention nationally and maintains a small buprenorphine practice. Her international experience has included consulting on drug user health in Ukraine and in Zanzibar with various international agencies. Dr. Stancliff has been the medical director of a methadone program and has worked in several capacities with syringe exchange programs.  She has served on the board of the New York Society of Addiction Medicine for four years. She has also published research on overdose prevention, syringe access and buprenorphine provision. 

TIMOTHY WIEGAND, MD

Timothy J. Wiegand, MD, FACMT, is board certified in internal medicine, medical toxicology and clinical pharmacology. He completed his Postgraduate Fellowships in Medical Toxicology and Clinical Pharmacology at the University of California, San Francisco. He is currently the Director of Toxicology at the University of Rochester Medical Center where he holds an appointment in Emergency Medicine as Associate Clinical Professor of Emergency Medicine at Strong Memorial Hospital and Highland Hospital.  Additionally, Dr. Wiegand Directs the Toxicology Consult Service at Strong Memorial and Highland Hospitals, serves as Medical Director of Huther-Doyle Chemical Dependency treatment program in Rochester, NY, and treats acute alcohol and opioid withdrawal at the Syracuse Behavioral Health (SBH) Rochester detoxification facility. 

He is also faculty for the SUNY Upstate Medical Toxicology Fellowship training program and serves as on-call toxicologist for the SUNY Upstate Poison Center.  Dr. Wiegand directs a clinical rotation in medical toxicology for the Strong Memorial Hospital Emergency Medicine residency program and is involved in toxicology, pharmacology and addiction medicine education for fellows, residents, and students in pharmacy and medicine. Dr. Wiegand won the 2013 American Society of Addiction Medicine (ASAM) Annual MedSci research award for best abstract for research involving addiction medicine education.  Dr. Wiegand is the Chair for the American College of Medical Toxicology (ACMT) Addiction Medicine section and he was appointed to the New York chapter of the American Society of Addiction Medicine (NYSAM) Board of Governors as Communication Committee Chair and Board Member in 2013.  He has been increasingly active in ASAM and in his state chapter, NYSAM, since 2011.